Veru Results, Progress of Enobosarm Weight Loss Clinical Program

 

• Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy^®*) for high quality weight loss is actively enrolling
• Company assembles weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise
• Company to present this month at upcoming American Association of Clinical Endocrinology annual meetingand GLP-1 Based Therapeutics Summit
• Company to host conference call and webcast today at 8:00 a.m. ET

The audio webcast will be accessible under the Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay will be available at approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international), passcode 8861692, for one week.

https://www.biospace.com/article/releases/veru-reports-fiscal-2024-second-quarter-financial-results-and-progress-of-its-enobosarm-high-quality-weight-loss-clinical-program/